While Spyre Therapeutics Inc has underperformed by -8.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SYRE fell by -31.26%, with highs and lows ranging from $47.97 to $18.26, whereas the simple moving average fell by -35.57% in the last 200 days.
On September 04, 2024, Wedbush started tracking Spyre Therapeutics Inc (NASDAQ: SYRE) recommending Outperform. A report published by Evercore ISI on July 16, 2024, Initiated its previous ‘Outperform’ rating for SYRE. Robert W. Baird also rated SYRE shares as ‘Outperform’, setting a target price of $50 on the company’s shares in an initiating report dated May 02, 2024. Wells Fargo March 01, 2024d the rating to Overweight on March 01, 2024, and set its price target from $12 to $35. BTIG Research initiated its ‘Buy’ rating for SYRE, as published in its report on December 20, 2023. Jefferies’s report from December 11, 2023 suggests a price prediction of $31 for SYRE shares, giving the stock a ‘Buy’ rating. Guggenheim also rated the stock as ‘Buy’.
Analysis of Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -42.90% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.26, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and SYRE is registering an average volume of 560.37K. On a monthly basis, the volatility of the stock is set at 7.54%, whereas on a weekly basis, it is put at 10.75%, with a loss of -15.62% over the past seven days. Furthermore, long-term investors anticipate a median target price of $58.62, showing growth from the present price of $17.94, which can serve as yet another indication of whether SYRE is worth investing in or should be passed over.
How Do You Analyze Spyre Therapeutics Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.13%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 93.56% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SYRE shares are owned by institutional investors to the tune of 93.56% at present.
